another mention of todays celgene conference call. trial should be starting soon. celgene talking about a pre clinical asset on 2 conference calls in a row is huge imho
(8/15/14) Update on the anti-CD47 cancer therapy clinical trials
The phase-1 clinical trial of the anti-CD47 antibody is designed to test its safety. The trial will accrue one patient per month at very low doses, and the first groups of participants have been identified from among current Stanford Cancer patients. Currently we are not recruiting new patients to this trial.
If enrollments do open up in the future, that information will be posted on this page. When and if enrollments open up, potential inclusion in this phase-1 trial will be based solely on physician referrals. If there are openings for new participants, and if you meet certain requirements, information posted on this page will describe how your physician can submit a request to the clinical trials team to consider your participation.
Given the limited nature of this safety trial, we urge that patients not delay or forgo recommended treatments in hopes of participating in this research effort.
being that we are basically one of the only publicly traded companies that has cd47 in the near term pipeline any sort of efficacy would be a positive and read through to trillium.
“Thirty days from now, the first cancer patient will be treated at Stanford,” Weissman said.
google: McLaughlin Research Institute conference highlights ingenuity
Investron: Do you hear that? That is the sound of money coming out of $arwr and rotating into $tkmr. If you would have spent more time reading about tekmira on this board rather than touting arrowhead you might have learned that tekmira has Small float, Safe and multi generational delivery, 7 triggers owed to us by alny, animal rule/fast track tkm-ebola, new orphan drug candidate to be announced, deal with agriculture co. Monsanto, potential royalties from patisiran phase 3 currently, messenger RNA delivery, ebola/marburg combo opportunities... shall i go on. Oh and treating chronic hbv patients in 9 months with our third gen delivery with multiple triggers. sigh
google that title above... sounds like weissman is close to filing NDA for cd47!
I think you mean Thursday and not tomorrow. I hope Dan addresses the pain us shareholders have endured. 907 3x dosing details will be interesting to me.
I have talked to Dan and Mani numerous times. I sold half my position last week to take an opportunity in TKMR as this seems to be dead money. I also ponied up the money to go to shareholders meeting last year to meet these guys face to face. I was impressed with Ali but must say that Dan can't bring any $$ into the company. Look at BMO giving us 3 dollar target with 0 valuation on our internal assets. I do like the IAP if it gets lifted and 907 still could be interesting but I think Dan and our Chairman McNab need to go.
google: RNAi may hold key to glyphosate resistance
have to wonder if that is tkmr being used. sounds like agri biz and rna is just taking off
you are a pretty dumb short i will give you that. go look at alny mcap dumb dumb
i agree this could be really big and open up even more avenues for tkmr.... so many ways to win with this one and still a low mcap. back out cash and low enterprise val. as well.
Late-Breaking Presentation 4:30
Ian MacLachlan, Ph.D.Recent Advances in the Lipid Nanoparticle-Mediated Delivery of Messenger RNA
Seven products based on Tekmira's lipid nanoparticle (LNP) delivery platform have entered clinical trials providing increasingly robust proof of clinical activity in multiple disease areas using small interfering RNA as the active pharmaceutical ingredient. We have recently applied the LNP technology to the efficient encapsulation and delivery of chemically modified mRNA in preclinical models demonstrating robust expression in numerous healthy tissues and tumors following intravenous administration. These encouraging results, orders of magnitude greater than that achieved using previously published, commercially available delivery agents, suggest that there may be numerous opportunities for the development of mRNA therapeutics using LNP delivery.
Ian MacLachlan, Ph.D., Executive Vice President and Chief Technology Officer, Tekmira Pharmaceuticals Corp., Canada